TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03451396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast
Description: All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast
Description: All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID
Study: NCT04324229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 6 MG/ML [Victoza]
Description: Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
Study: NCT03011996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR 500mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR 500mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR 500mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR 500mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLR 500mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Study: NCT04417465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-579
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-579
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-579
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-579
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-579
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-579
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR TKI
Description: Oral Tablet
Study: NCT03396276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: 8mg of buprenorphine/2mg of naloxone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief counseling in the ED
Description: Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to outpatient treatment
Description: A referral will be made to one of the affiliated MAT clinics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up coaching
Description: A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
Study: NCT03578887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Program
Description: Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program (DPP).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
Description: Subjects undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy with their own surgical team
Study: NCT01967147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propylene Glycol, 0.6% eye drops
Description: Commercially available eye drops used during Treatment Phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative-free 0.9% Saline solution
Description: Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
Study: NCT01844024

Intervention type: OTHER
Group type: OTHER
Intervention: misoprostol by midwife
Description: Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
Study: NCT02081430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Manipulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper trapezius stretch
Study: NCT02588105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0156
Description: All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Module 1 combination with olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Module 2 combination with irinotecan/FOLFIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Module 2 combination with irinotecan/FOLFIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Module 2 combination with irinotecan/FOLFIRI
Study: NCT02207504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is an ATP-competitive small-molecule inhibitor of the ALK, c-Met/HGFR, RON, and ROS receptor tyrosine kinases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is an androgen receptor signaling inhibitor.
Study: NCT01056705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Poliomyelitis Vaccine
Description: Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Salk strains).
Description: 3x0.5ml intramuscular injections, one month apart.
Study: NCT04270591

Intervention type: DRUG
Group type: OTHER
Intervention: Glumetinib
Description: The investigational product will be orally administrated when fasting at dose level of 300mg QD
Study: NCT01980680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone and Estradiol
Study: NCT04222764

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time three-dimensional echocardiography
Description: The initial hemodynamic assessment and monitoring using echocardiography will be performed within 12h following ICU admission. TTE will be performed systematically as first-line examination and TEE will be performed only on ventilated and sedated patients for whom additional information is required for their management, according to the standards of care of the participating centers. In that case, TEE will be performed immediately after TTE.~3D echocardiographic measurements will be performed after the examination by two independent intensivists expert in critical care echocardiography who will be blinded from the usual parameters of RV systolic functions; these parameters will be measured during the examination to guide the management of patients, according to the standard of care of the participating centers.
Study: NCT04725877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-1111
Description: VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.
Study: NCT02227979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Purple Cry Intervention
Description: This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
Study: NCT00979550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: commercially available topical antiviral drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non-medicated petroleum cream
Description: Over the counter topical cream used to aid the healing process in skin lesions
Study: NCT03304197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypotonic
Description: N/A: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isotonic
Description: N/A: see arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: N/A: see arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydrated
Description: N/A: see arm description
Study: NCT04110704

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of transvaginal cerclage
Description: Transvaginal cerclage is inserted in women with a high risk of preterm birth. However it is unknown whether this alongside cervical length monitoring improves the incidence of preterm birth. The cerclage is inserted under regional analgesia.
Study: NCT03011996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg
Description: Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX 1g
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX 1g
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX 1g
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX 1g
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMX 1g
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Cohort 2: bid for 7 days
Study: NCT01208272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy (IPT)
Study: NCT02414282

Intervention type: DRUG
Intervention: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT04264572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meals
Description: MTM are meals designed by a Registered Dietitian Nutritionist to reflect appropriate dietary therapy according to evidence-based nutrition practice guidelines. They address medical diagnoses, symptoms, allergies, inability to chew or swallow, medication management, and side effects to ensure the best possible nutrition-related health outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meals
Description: MTM are meals designed by a Registered Dietitian Nutritionist to reflect appropriate dietary therapy according to evidence-based nutrition practice guidelines. They address medical diagnoses, symptoms, allergies, inability to chew or swallow, medication management, and side effects to ensure the best possible nutrition-related health outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Medical Nutrition Therapy (tele-MNT)
Description: Medical nutrition therapy (MNT) is offered as a component of usual care in many health systems, and consists of individuals receiving nutrition education tailored to their unique medical needs. Tele-MNT is the use of video technology to deliver MNT.
Study: NCT01271647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yin and Yang tonic granules
Description: Yin and Yang tonic granules,18g per time,two times per day,six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: granules,18g per time,two times per day,six months
Study: NCT02772666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O-Glass
Description: The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Swinging Flashlight Test
Description: The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
Study: NCT03544853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic socket for transtibial amputee
Description: To wear a prosthetic socket for evaluation of comfort and biomechanical metrics such as skin loading conditions.
Study: NCT03753698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin
Description: Implantation of device electrodes subcutaneous in lower tibia area;~Stimulation of posterior tibial nerves:~Regimen 1 (months 0-3): Six stimulation treatments per week, one stimulation per day, for duration of 30 minutes each Regimen 2 (months 3-6): Three stimulation treatments per week, one stimulation per day, for duration of 30 minutes each. Stimulation is activated by the patient.
Study: NCT02117453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03339245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose Solution (75 Grams)
Description: Fructose given in divided doses at breakfast and dinner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose Solution (75 Grams)
Description: Fructose given in divided doses at breakfast and dinner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Solution (75 grams)
Description: Glucose given in divided doses at breakfast and dinner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Solution (75 grams)
Description: Glucose given in divided doses at breakfast and dinner.
Study: NCT01342341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parafon Forte
Description: Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parafon Forte
Description: Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit
Study: NCT02880410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroBlate System
Description: Laser Interstitial Thermal Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation therapy and temozolomide
Description: Radiation therapy and temozolomide
Study: NCT00727311

Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031) injector
Description: PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
Study: NCT02952534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered daily
Study: NCT04196491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: CAR-T Cell Therapy
Study: NCT01046864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
Study: NCT04196491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Maintenance Therapy
Study: NCT01684787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a + ribavirin in normal ALT
Description: peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a + ribavirin in elevated ALT
Description: peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
Study: NCT00962377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endomyocardial biopsy
Description: Right ventricular endomyocardial biopsy in monitoring of asymptomatic heart transplant patients for acute cellular rejection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: AlloMap Molecular Testing
Description: Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
Study: NCT03995862

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire should be completed by the patient the day of inclusion. Health data will be collected in patients medical file from inclusion to the date of the end of study (i.e. no follow-up for the last patient included and a maximum of three years of follow-up for the first patient included).
Study: NCT03341325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animal-assisted activity
Description: a live animal (small dog and/or rabbit)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control activity
Description: a stuffed toy animal
Study: NCT04075877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS
Description: See prior section.
Study: NCT02780908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded exercise testing
Description: All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Graded exercise testing
Description: All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting testing
Description: The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resting testing
Description: The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
Study: NCT03730129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hizentra
Description: Subjects will receive Hizentra 0.4 mg/kg qweekly subcutaneously for 6 months (24 weeks)
Study: NCT00658255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Study: NCT03053687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation standardized formula
Description: Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low caloric formula (Powder added to water) without added vitamins and mineral
Study: NCT01395459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR only
Description: As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR+PCC
Description: Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR